ABVC BIOPHARMA, INC. (ABVC) Earnings
ABVC BIOPHARMA, INC.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Mar 3, 2026
From the latest earnings 8-K
Revenue • FY2025
$296K
▼ 69.5%YoY
Diluted EPS • FY2025
-$0.39
▲ 22.0%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from ABVC's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $296K | -$7.91M | — | -$0.39 | — | -2416.0% | -41.9% |
| FY2022 | $969.8K | -$16.42M | $683.4K | -$0.50 | -$7.52M | -1558.5% | +172.6% |
| FY2021 | $355.8K | -$12.04M | $350.7K | -$0.51 | -$7.62M | -3290.1% | -26.3% |
| FY2020 | $483K | -$10.59M | $464.3K | -$0.50 | — | -1760.9% | -31.2% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Mar 3, 2026 | 8-K (2.02) | 0001213900-26-023054EDGAR |
| Nov 3, 2025 | 8-K (2.02) | 0001213900-25-104900EDGAR |
| Aug 14, 2025 | 8-K (2.02) | 0001213900-25-076018EDGAR |
| May 1, 2025 | 8-K (2.02) | 0001213900-25-038060EDGAR |
| Apr 15, 2025 | 8-K (2.02) | 0001213900-25-032135EDGAR |
| Nov 14, 2024 | 8-K (2.02) | 0001213900-24-097894EDGAR |
| Aug 15, 2024 | 8-K (2.02) | 0001213900-24-069338EDGAR |
| Mar 14, 2024 | 8-K (2.02) | 0001213900-24-022396EDGAR |
Never miss a ABVC filing.
Get an email when ABVC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.